MARKET

TCON

TCON

Tracon Pharmaceu
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.800
0.000
0.00%
Opening 10:58 05/27 EDT
OPEN
1.790
PREV CLOSE
1.800
HIGH
1.805
LOW
1.780
VOLUME
10.37K
TURNOVER
13.77K
52 WEEK HIGH
7.42
52 WEEK LOW
1.607
MARKET CAP
36.14M
P/E (TTM)
-0.9830
1D
5D
1M
3M
1Y
5Y
Eucure Biopharma To Present Clinical Data From YH003 (anti-CD40 mAb) And YH001 (anti-CTLA-4 mAb) Trials At 2022 American Society Of Clinical Oncology (ASCO) Annual Meeting. BZ NOTE: TRACON Entered Into Agreement For Development Of YH001
Eucure Biopharma, a wholly owned subsidiary of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen"), today announced that it will present two posters at the 2022 ASCO Annual Meeting, taking place
Benzinga · 3d ago
TRACON Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-indepen...
GlobeNewswire · 05/16 12:05
Recap: TRACON Pharma Q1 Earnings
TRACON Pharma (NASDAQ:TCON) reported its Q1 earnings results on Wednesday, May 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings TRACON Pharma missed estimated earnings by 14.29%, reporting an EPS of $-0.48 versus an...
Benzinga · 05/11 21:24
BRIEF-TRACON Expects Current Cash And Cash Equivalents Will Fund Operations Into 2023
reuters.com · 05/11 20:50
TRACON Pharmaceuticals Q1 EPS $(0.48) Misses $(0.42) Estimate
TRACON Pharmaceuticals (NASDAQ:TCON) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.42) by 14.29 percent. This is a 45.45 percent decrease over losses of $(0.33) per
Benzinga · 05/11 20:03
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/11 13:37
Tracon Q1 2022 Earnings Preview
Tracon (NASDAQ:TCON) is scheduled to announce Q1 earnings results on Wednesday, May 11th, after market close. The consensus EPS Estimate is -$0.42 Over the last 3 months, EPS estimates have
Seekingalpha · 05/10 21:35
A Preview Of TRACON Pharmaceuticals's Earnings
TRACON Pharmaceuticals (NASDAQ:TCON) is set to give its latest quarterly earnings report on Wednesday, 2022-05-11. Here's what investors need to know before the announcement. Analysts estimate that TRACON Pharmaceuticals will report an earnings per share (...
Benzinga · 05/10 15:07
More
No Data
Learn about the latest financial forecast of TCON. Analyze the recent business situations of Tracon Pharmaceu through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

37.50%Strong Buy
50.00%Buy
12.50%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average TCON stock price target is 10.38 with a high estimate of 14.00 and a low estimate of 7.00.
High14.00
Average10.38
Low7.00
Current 1.800
EPS
Actual
Estimate
-0.46-0.35-0.23-0.12
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 49
Institutional Holdings: 9.64M
% Owned: 48.03%
Shares Outstanding: 20.08M
TypeInstitutionsShares
Increased
10
532.11K
New
5
23.09K
Decreased
7
530.44K
Sold Out
4
41.36K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.06%
Pharmaceuticals & Medical Research
+0.47%
Key Executives
President/Chief Executive Officer/Director
Charles Theuer
Chief Financial Officer/Chief Accounting Officer
Scott Brown
Other
Mark Wiggins
Director
Carol Lam
Independent Director
Lisa Johnson-pratt
Independent Director
William LaRue
Independent Director
Martin Mattingly
Independent Director
Saundra Pelletier
Independent Director
J. Rainer Twiford
Independent Director
Stephen Worland
No Data
No Data
About TCON
TRACON Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of targeted therapeutics for cancer. The Company's product pipelines consist of Envafolimab (KN035), Methoxyamine (TRC102), TJ004309 and Bispecific Antibodies. KN035 is a single-domain PD-L1 antibody that is administered by subcutaneous injection without the need for an adjuvant. KN035 is in Phase II of clinical trials. TRC102 is a clinical-stage small molecule inhibitor of the DNA base excision repair pathway, which is a pathway that causes resistance to alkylating and antimetabolite chemotherapeutics. TRC102 is in multiple Phase I and Phase II clinical trials. TJ004309 is a humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine, which is an immunosuppressive metabolite adenosine.

Webull offers kinds of TRACON Pharmaceuticals Inc stock information, including NASDAQ:TCON real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TCON stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TCON stock methods without spending real money on the virtual paper trading platform.